Clemastine to study MRI changes in relapsing MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This early-phase study tests whether clemastine (a drug being studied for “myelin repair”) changes how MS looks on special MRI scans. It may help researchers understand if the treatment supports restoring nerve covering in people with relapsing-remitting MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign a consent form before any study testing starts
- You have relapsing-remitting multiple sclerosis and have had MS for under 15 years
- You are age 18 to 55
- You must be able to use effective birth control if you can become pregnant, or you must not be able to become pregnant
- Your most recent MRI (within 3 months) must not show a new MS lesion
- You cannot have severe disability (EDSS 4.5 or higher) or major MRI brain shrinkage for your age
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called clemastine fumarate (an antihistamine) can help repair the protective coating around nerves in people with relapsing-remitting multiple sclerosis. Researchers will use MRI scans to see if the drug improves lesion healing over time.
This study uses detailed imaging (mostly MRI) to look for patterns that may explain why multiple sclerosis can worsen. It may help researchers understand the biology behind neurodegeneration and improve future care.
This study collects health information and samples from people with multiple sclerosis (MS) in different stages to help develop better tools for managing the disease. By participating, you could help researchers use data science to improve MS care.
This Phase 2 trial tests whether clemastine can help regrow the protective covering around the optic nerve after acute optic neuritis (an inflammation-related vision problem). It may help improve vision recovery and signal how well “remyelination” happens.
This study tests whether N-acetyl cysteine (a supplement-like medicine) changes body and brain function in people with multiple sclerosis. It may help researchers understand how it affects brain chemistry and activity using special brain imaging.
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.